Matches in Nanopublications for { ?s ?p "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP460082.RAhwv5ojQ4BHb6bg9HpthFq0Od8k_HVShj4A_vd9xpFhk130_assertion description "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP460082.RAhwv5ojQ4BHb6bg9HpthFq0Od8k_HVShj4A_vd9xpFhk130_provenance.
- assertion description "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP557458.RAPjXGrpOfmcwiAYCp4eSPyttL1lrZweP-ykl6X_h6fdM130_assertion description "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557458.RAPjXGrpOfmcwiAYCp4eSPyttL1lrZweP-ykl6X_h6fdM130_provenance.
- NP519361.RAv_bgMabkRCcJOvoaLxBYTFD6LvhX1ZR3OFVtrgFBl50130_assertion description "[Depending on the biological background of individual patients, heterozygous and homozygous JAK2 V617F ET/PV may preferentially induce myeloid metaplasia with myelofibrosis with a relative suppression of megakaryocytic and erythropoietic myeloproliferation leading to clinical pictures of fibrotic chronic idiopathic myelofibrosis (CIMF) or agnogenic myeloid metaplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519361.RAv_bgMabkRCcJOvoaLxBYTFD6LvhX1ZR3OFVtrgFBl50130_provenance.